Evidence map›Paper›PMID 35413489›Full record

ReviewCancer treatment reviews2022

Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.

Bradley J Monk, Takayuki Enomoto, W Martin Kast, Mary McCormack, David S P Tan, Xiaohua Wu, Antonio González-Martín

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer treatment reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 4 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 4 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 6 countries.

Bradley J MonkHonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School, Phoenix, AZ, USA. Electronic address: bmonk@gog.org.
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, 2-5274 Gakkocho-dori, Niigata 951-8514, Japan. Electronic address: enomoto@med.niigata-u.ac.jp.
W Martin KastMolecular Microbiology & Immunology, Norris Comprehensive Cancer Center, University of Southern California, 1450 Biggy Street, Los Angeles, CA 90033, USA. Electronic address: Martin.Kast@med.usc.edu.
Mary McCormackDepartment of Oncology, University College Hospital London, London NW1 2BU, UK. Electronic address: mary.mccormack2@nhs.net.
David S P TanDepartment of Haematology-Oncology, National University Cancer Institute Singapore, NUHS Tower Block, Level 7, 1E Kent Ridge Road, Singapore 119228, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, Cancer Science Institute of Singapore, National University of Singapore, NUHS Tower Block, Level 7, 1E Kent Ridge Road, Singapore 119228, Singapore. Electronic address: david_sp_tan@nuhs.edu.sg.
Xiaohua WuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dong-an Road, Shanghai 200032, China. Electronic address: wu.xh@fudan.edu.cn.
Antonio González-MartínMedical Oncology Department, University of Navarra Clinic, 28027 Madrid, Spain; Program for Translational Research in Solid Tumors at Center for Applied Medical Research, 31008 Pamplona, Spain. Electronic address: agonzalezma@unav.es.
Creighton University · USFudan University Shanghai Cancer Center · CNNational University Cancer Institute, Singapore · SGNiigata University · JPUniversidad de Navarra · ESUniversity College London · GBUniversity of Southern California · US

Funding

VLP VACCINES AGAINST HPV INDUCED TUMORSR01CA074397 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 1997 to 2020
$5.5M
NCI NIH HHS R01 CA074397
6 · The paper itself

Abstract

Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Before 2021, pembrolizumab was the only United States Food and Drug Administration-approved immunotherapy in cervical cancer, specifically for the second-line recurrent or metastatic (r/m) setting. In late 2021, the antibody-drug conjugate tisotumab vedotin was approved for second-line r/m cervical cancer and pembrolizumab combined with chemotherapy ± bevacizumab was approved for first-line r/m disease based on results from KEYNOTE-826. Moreover, with at least 2 dozen additional immunotherapy clinical trials in the second-line and first-line r/m setting, as well as in locally advanced disease, the treatment landscape for cervical cancer may eventually encounter a potential paradigm shift. Pivotal trials of immunotherapies for cervical cancer that were recently approved or with the potential for regulatory consideration through 2024 are reviewed. As immunotherapy has the opportunity to establish new standards of care in the treatment of cervical cancers, new biomarkers to identify the ideal patient populations for these therapies may also become important. However, issues with access, affordability, and compliance in low- and middle-income countries are anticipated.

Indexed as

Uterine Cervical NeoplasmsFemaleHumansImmunologic FactorsImmunotherapyNeoplasm Recurrence, LocalUnited StatesImmunologic FactorsCervical cancerImmunotherapyLocally advancedMetastatic

Identifiers

PMID35413489
PMCPMC10697630
OpenAlexW4220655380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.